This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

King W. To, MD; William G. Tsiaras, MD; Walter R. Thayer, MD
Providence, RI

Arch Ophthalmol. 1995;113(11):1354.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In the September 1994 issue of the ARCHIVES, Dr Saran and colleagues¹ reported the association of acute hypopyon uveitis in patients with acquired immunodeficiency syndrome (AIDS) who had been treated for systemic Mycobacterium avium complex infection with rifabutin. Other investigators^2-4 have also noted an association of uveitis with rifabutin use in their patients with human immunodeficiency virus infection.

In this country, rifabutin has been approved for only a handful of uses, such as the prophylactic treatment for disseminated M avium complex infections in patients with advanced AIDS. Other approved uses for this drug include treatment of refractory cases of pulmonary tuberculosis and inflammatory bowel disease (IBD).

We would like to share our experience with the use of rifabutin in the treatment of IBD. Ten years ago, one of us (W.R.T.) noted that when a Mycobacterium species that was isolated from the diseased bowels of two patients with Crohn's . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?